Neurosurgical lesioning for Tourette syndrome – Authors’ reply

Related Articles:

• Neurosurgical lesioning for Tourette syndrome - Authors' reply March 17, 2023 Lancet Neurol. 2023 Apr;22(4):292-293. doi: 10.1016/S1474-4422(23)00079-0.NO ABSTRACTPMID:36931795 | DOI:10.1016/S1474-4422(23)00079-0
• Neurosurgical lesioning for Tourette syndrome - Authors' reply March 17, 2023 Lancet Neurol. 2023 Apr;22(4):292-293. doi: 10.1016/S1474-4422(23)00079-0.NO ABSTRACTPMID:36931795 | DOI:10.1016/S1474-4422(23)00079-0
• Neurosurgical lesioning for Tourette syndrome - Authors' reply March 17, 2023 Lancet Neurol. 2023 Apr;22(4):292-293. doi: 10.1016/S1474-4422(23)00079-0.NO ABSTRACTPMID:36931795 | DOI:10.1016/S1474-4422(23)00079-0
• Neurosurgical lesioning for Tourette syndrome - Authors' reply March 17, 2023 Lancet Neurol. 2023 Apr;22(4):292-293. doi: 10.1016/S1474-4422(23)00079-0.NO ABSTRACTPMID:36931795 | DOI:10.1016/S1474-4422(23)00079-0
• Animals in Parkinson's research October 22, 2022 Saturday 22 October 2022  Continuing with the theme of animal models, here is an essay I wrote as part of my MSc neuroscience about the use of animals in Parkinson’s research. Many people, myself included, feel uncomfortable about the use of animals in brain research, an issue for which there are no easy answers. There is quite a bit of…
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Tourette syndrome: clinical features, pathophysiology, and treatment November 10, 2022 Lancet Neurol. 2022 Oct 28:S1474-4422(22)00303-9. doi: 10.1016/S1474-4422(22)00303-9. Online ahead of print.ABSTRACTTourette syndrome is a chronic neurodevelopmental disorder characterised by motor and phonic tics that can substantially diminish the quality of life of affected individuals. Evaluating and treating Tourette syndrome is complex, in part due to the heterogeneity of symptoms and comorbidities between individuals. The underlying pathophysiology of Tourette syndrome is…
• The radiologist at a Parkinson’s conference October 24, 2022 # # # # In 2015, a woman with dementia was sitting in hospice care, wheelchair-bound and largely non-communicative. As part of a research project, she was given repeated computed tomography (CT) scans of her brain. The effect of this seemingly harmless treatment was rather astonishing, and it has led to more research exploring the effect of low dose ionizing…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Monthly Research Review – October 2022 October 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Immunomodulating Activity of an Extract from Ashwagandha: Implications for Treatment of Parkinson’s March 15, 2023 “The mind, in addition to medicine, has powers to turn the immune system around.” Jonas Salk “As you begin to heal the inner you, you alter your immune system.” Wayne Dyer Introduction: The current blog post is focused on reviewing an immunomodulating action of an extract from Ashwagandha. Furthermore, I will comment on the use of Ashwagandha for treating Parkinson’s.…
• Parkinson’s and Autoimmunity January 26, 2023 “I am always doing that which I cannot do, in order that I may learn how to do it.” Pablo Picasso “We have more possibilities available in each moment than we realize.” Nhat Hanh Précis: This post exists because I received a note from a reader concerned about using a substance that potentially was an immune enhancer, coupled with the…
• Monthly Research Review – November 2022 November 30, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
• A nod to immunomod with fingolimod October 16, 2022 # # # # In general, your immune system does a truly amazing job of keeping you healthy and the dangerous pathogenic world around us at bay. Trillions of cells constantly monitoring for viruses and other illness-causing agents, and ruthlessly disposing of any that they actually find. But sometimes your immune system can get a little carried away with this…
• The trans-omics of -omics November 18, 2022 # # # # “Precision medicine” is an emerging model of therapeutic intervention in which treatment options are tailored to a specific subtype of a condition or even on an individual patient-based metric that involves an intergrated analysis of his/her comprehensive “-omics” data. Many different methods of stratifying patients have been proposed and many of them involve adding the word…
• Apathy and Parkinson’s August 18, 2021 “Apathy is the acceptance of the unacceptable.” John Stott “I don’t know, I don’t care, and it doesn’t make any difference.” Jack Kerouac Definition: Apathy (ap·a·thy, /ˈapəTHē/) lack of interest, enthusiasm, or concern. Occurrence of Apathy in Parkinson’s: The presence of apathy in Parkinson’s is between 17% to 70%, the wide range is partly due to the imprecise clinical definition…
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study March 26, 2021 Lancet Neurol. 2021 Mar 23:S1474-4422(21)00027-2. doi: 10.1016/S1474-4422(21)00027-2. Online ahead of print.ABSTRACTBACKGROUND: The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia.METHODS: EFACTS is a prospective, observational…
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study March 26, 2021 Lancet Neurol. 2021 Mar 23:S1474-4422(21)00027-2. doi: 10.1016/S1474-4422(21)00027-2. Online ahead of print.ABSTRACTBACKGROUND: The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia.METHODS: EFACTS is a prospective, observational…
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study March 26, 2021 Lancet Neurol. 2021 Mar 23:S1474-4422(21)00027-2. doi: 10.1016/S1474-4422(21)00027-2. Online ahead of print.ABSTRACTBACKGROUND: The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia.METHODS: EFACTS is a prospective, observational…
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study March 26, 2021 Lancet Neurol. 2021 Mar 23:S1474-4422(21)00027-2. doi: 10.1016/S1474-4422(21)00027-2. Online ahead of print.ABSTRACTBACKGROUND: The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia.METHODS: EFACTS is a prospective, observational…
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study March 26, 2021 Lancet Neurol. 2021 Mar 23:S1474-4422(21)00027-2. doi: 10.1016/S1474-4422(21)00027-2. Online ahead of print.ABSTRACTBACKGROUND: The European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich's ataxia. We aimed to assess progression characteristics and to identify patient groups with differential progression rates based on longitudinal 4-year data to inform upcoming clinical trials in Friedreich's ataxia.METHODS: EFACTS is a prospective, observational…